Sep 13, 2006|
Pharma: Assessing R&D value...
Indian pharma companies have been making strides in R&D after the introduction of the product patent law in the country. That said, it takes around 10 to 12 years for an NCE (new chemical entity) to hit the market and the top Indian companies namely, Dr. Reddy's, Ranbaxy, Wockhardt, Sun Pharma, Nicholas Piramal and Biocon, are investing anywhere between 5% to 10% of their annual revenues in R&D activities. This, considering the resource crunch that domestic companies face, is by no means a small amount.
The problem associated with valuing an R&D pipeline is that the revenues generated do not match the expenses undertaken. This is because the success ratio of a molecule hitting the market is considerably low. However, the R&D costs borne by the company include costs incurred for both successful and unsuccessful molecules. Globally, the historical average for the pharma industry R&D productivity has been just over one NCE launch per year. In comparison, Indian pharma companies have yet to launch a single NCE in the market and hence the valuation of the pipeline becomes all the more difficult. That said, it becomes important to keep a track of the progress of the NCE through various stages. Here we enumerate some of the factors that investors need to be aware of with regards the R&D pipeline of pharma companies.
Stage of clinical trials: The progress of a molecule (whether it is in the pre-clinical stage or Phase III or so) is important as it gives a rough idea of possible launch dates of the molecules if all goes well. However, the risk of failure increases significantly, the further the drug is from the market.
Number of molecules under development: It is important for pharma companies to strike a balance by having various molecules in different stages of clinical trials. This is to ensure a steady flow of drugs into the market in the future. It must be noted that the risk of a failure has been currently estimated at 9 out of 10 in Phase I, 6 out of 10 in Phase II and 5-6 out of 10 in Phase III (Source: Deutsche Bank). As far as domestic companies are concerned, most of the molecules under development are either in the pre-clinical, Phase I or Phase II clinical trials.
Therapeutic area targeted: Assuming that a company is developing a drug for treating a disease for which there is already a well-established market, the potential of the same could be estimated by determining the likely market share that this molecule would garner. In this scenario, the company's marketing and distribution network and the potential advantages of the drug over drugs of a similar kind in the market will be crucial factors. If the targeted therapeutic area is one where there is not much competition, then the potential for the same could be roughly estimated by considering the likely number of patients and the likely price for the drug.
To sum up...
While global pharma companies are developing molecules through the entire stage of clinical trials on their own, domestic pharma companies, which are facing resource constraints, are looking to develop molecules through collaboration and out-licensing. Typically, a drug begins to generate revenues only after it is launched in the market. However in the case of out-licensing, a molecule begins to generate revenues (in the form of milestone receipts) before the launch itself, depending upon the progress of the same. In this case, future earnings can be calculated by discounting future milestone receipts. Whatever be the case, while valuing the R&D pipeline, the risk of failure cannot be ignored. In fact, domestic pharma companies such as Ranbaxy and Dr. Reddy's have faced failures in the past.
As far as valuations are concerned, those companies, which have a strong product pipeline generally, tend to enjoy higher valuations as compared to others. For instance, MNC pharma companies such as GSK Pharma and Aventis have earned higher valuations as compared to domestic companies based on the fact that the former can leverage on the R&D pipeline and products of their research-intensive parent companies. Going forward, the years 2009 and 2010 could be the turning point for domestic pharma companies if the R&D programme stays on track. Key molecules to watch out for will be Glenmark's 'Oglemilast' for asthma/COPD, Dr. Reddy's 'Balaglitazone' for diabetes and Ranbaxy's 'RBx 11160' for malaria.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
Aug 21, 2017
PersonalFN explains the chief factor pushing gold prices up of late.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407